Drug-Induced Liver Disease

Herausgeber: Kaplowitz, Neil; Deleve, Laurie D

• Gebundenes Buch

Produktbeschreibung

The 3e of Drug-Induced Liver Disease provides a comprehensive treatment of the field of drug-induced liver disease from mechanisms of liver injury, diagnosis and management, major hepatotoxins, regulatory perspectives and global approaches to assessment and solutions. Containing 4 new chapters and 16 new chapter authors, this edition has been thoroughly revised with the latest research and findings related to drug-induced liver disease. Intended for medical specialists, including gastroenterologists, hepatologists and pathologists, as well as toxicologists, regulatory professionals and scientists in the pharmaceutical industry, this book is the definitive reference on all clinical and practical aspects of drug-induced liver disease.

Produktdetails

• Verlag: Elsevier Health Sciences
• 3rd Revised edition
• Seitenzahl: 776
• Erscheinungstermin: 14. Mai 2013
• Englisch
• Abmessung: 284mm x 222mm x 45mm
• Gewicht: 2347g
• ISBN-13: 9780123878175
• ISBN-10: 0123878179
• Artikelnr.: 37043770

Inhaltsangabe

Part I. Mechanisms of Liver Injury Chapter 1: Drug-Induced Liver Injury:
Introduction and Overview Chapter 2: Cytochrome P450 Activation of Toxins
and Hepatotoxicity Chapter 3: Mechanistic Role of Acyl Glucuronides Chapter
4: Oxidative Stress, Antioxidant Defense and Liver Injury Chapter 5:
Hepatotoxicity due to Mitochondrial Injury Chapter 6: Mechanisms of Cell
Death and Relevance to Drug Hepatotoxicity Chapter 7: Role of Membrane
Transport in Hepatotoxicity and Pathogenesis of Drug-Induced Cholestasis
Chapter 8: Liver Sinusoidal Endothelial Cell and Liver Injury Chapter 9:
Macrophages and Kupffer Cells in Hepatotoxicity Chapter 10: Role of
Inflammation in Drug-Induced Liver Disease Chapter 11: Role of Adaptive
Immune System Chapter 12: Role of Tissue Repair in Liver Injury Chapter 13:
Genetic Factors in Pathogenesis
Part II. Diagnosis and ManagementChapter 14: Clinical Manifestations and
Management of Drug-Induced Liver Diseases Chapter 15: Histopathology of
Drug-Induced Liver Disease Chapter 16: Risk Factors for Drug-Induced Liver
Disease Chapter 17: The Promise of Genomics, Proteomics and Metabolomics of
Blood and Liver in the Diagnosis of Drug-Induced Liver Disease Chapter 18:
Causality Assessment
Part III. Hepatotoxicity of Specific DrugsChapter 19: Mechanisms of
Acetaminophen-Induced Liver Disease Chapter 20: Acetaminophen - Pathology
and Clinical Presentation of Hepatotoxicity Chapter 21: Mechanisms
Underlying the Hepatotoxicity of Non-Steroidal Anti-Inflammatory Drugs
Chapter 22: Non-Steroidal Anti-Inflammatory Drugs - Pathology and Clinical
Presentation of Hepatotoxicity Chapter 23: Mechanisms, Pathology and
Clinical Presentation of Hepatotoxicity of Anesthetic Agents Chapter 24:
Anticonvulsant AgentsChapter 25: Psychotropic Drugs and Drugs of Abuse
Chapter 26: Hepatotoxicity of Antimicrobials and Antifungal Agents Chapter
27: Antituberculosis Agents Chapter 28: Hepatotoxicity in Antiviral Agents
Chapter 29: Hepatotoxicity of Cardiovascular and Antidiabetic Drugs Chapter
30: Cancer Chemotherapy Chapter 31: Hepatotoxicity of Immunomodulating
Agents and the Transplant Situation Chapter 32: Methotrexate Chapter 33:
Hormones and Hormone Antagonists Chapter 34: Mushroom Poisoning: A Clinical
Model of Toxin-Induced Centrilobular Necrosis Chapter 35: Hepatotoxicity
and Herbal Medicines, Vitamins and Natural Hepatoxins Chapter 36:
Occupational and Environmental HepatotoxicityChapter 37: Chronic Liver
Disease from Drugs
Part IV. Future DirectionsChapter 38: Regulatory Perspectives Chapter 39:
Drug-Induced Liver Injury Networks Chapter 40: Liver Tox: The Future